Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis

Diabetologia

Volumn 49, Issue 2, 2006, Pages 405-420

  Gadau, S ^a   Emanueli, C ^a,b   Van Linthout, S ^a   Graiani, G ^a   Todaro, M ^c   Meloni, M ^a   Campesi, I ^a   Invernici, G ^d   Spillmann, F ^a   Ward, K ^a   Madeddu, P ^a,b,e  

^a NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF PALERMO   (Italy)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e IRCCS MULTIMEDICA   (Italy)

Author keywords

Advanced glycation end products; AGEs; Angiogenesis; Apoptosis; Benfotiamine; Caspase; Diabetes; Endothelial progenitor cells; Ischaemia; Vitamin B1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BENFOTIAMINE; CASPASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; TRANSKETOLASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INDUCTION; EXPERIMENTAL MODEL; HINDLIMB; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; LIMB ISCHEMIA; LIMB PERFUSION; MALE; MOUSE; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; STREPTOZOCIN DIABETES; TISSUE NECROSIS; TOE; VASODILATATION; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BODY WEIGHT; CASPASE 3; CASPASES; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DIETARY SUPPLEMENTS; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HEMODYNAMIC PROCESSES; IMMUNOHISTOCHEMISTRY; ISCHEMIA; MALE; MICE; MICE, INBRED STRAINS; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; STEM CELLS; THIAMINE;

EID: 31844452060     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-0103-5     Document Type: Article

References (52)

1. Ouriel K (2001) Peripheral arterial disease. Lancet 358:1257-1264
2. Hiatt WR (2001) Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344:1608-1621
3. Currie CJ, Morgan CL, Peters JR (1998) The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 21:42-48
4. Humphrey LL, Palumbo PJ, Butters MA et al (1994) The contribution of non-insulin-dependent diabetes to lower-extremity amputation in the community. Arch Intern Med 154:885-892
5. Regensteiner JG, Hiatt WR (2002) Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med 112:4957
6. Rivard A, Silver M, Chen D et al (1999) Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 154:355-363
7. Taniyama Y, Morishita R, Hiraoka K et al (2001) Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 104: 2344-2350
8. Emanueli C, Graiani G, Salis MB, Gadau S, Desortes E, Madeddu P (2004) Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in type 1 diabetic mice. Diabetes 53:1096-1103
9. Lederman RJ, Mendelsohn FO, Anderson RD et al (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359:2053-2058
10. Rajagopalan S, Mohler ER 3rd, Lederman RJ et al (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108:1933-1938
11. Simons M (2005) Angiogenesis. Where do we stand now? Circulation 111:1556-1566
12. The DCCT Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
13. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
14. Wei M, Gaskill SP, Haffner SM, Stern MP (1998) Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21:1167-1172
15. Ushio-Fukai M, Tang Y, Fukai T et al (2002) Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 91:1160-1167
16. Tojo T, Ushio-Fukai M, Yamaoka M, Ikeda S, Patrshev N, Alexander W (2005) Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation 111:2347-2355
17. Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 86:494-501
18. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
19. McClain DA, Paterson AJ, Roos MD, Wei X, Kudlow JE (1992) Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells. Proc Natl Acad Sci U S A 89:8150-8154
20. Giardino I, Edelstein D, Brownlee M (1994) Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 94:110-117
21. Schmidt AM, Hori O, Chen JX et al (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403
22. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M (2001) Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341-1348
23. Cai S, Khoo J, Channon KM (2005) Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc Res 65:823-831
24. Gerber HP, McMurtrey A, Kowalski J et al (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343
25. Dimmeler S, Fisslthaler B, Fleming I, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells via Akt-dependent phosphorylation. Nature 399:601-605
26. Kim I, Kim HG, So J-N et al (2000) Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ Res 86:24-29
27. Krankel N, Adams V, Linke A et al (2005) Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol 25:698-703
28. Dimmeler S, Aiche A, Vasa M et al (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest 108:391-397
29. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52: 2110-2120
30. Hammes HP, Du X, Edelstein D et al (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294-299
31. Shindo H, Okamoto K, Totsu J (1967) Transport of organic compounds through biological membranes. I. Accumulative uptake of S-benzoylthiamine by human erythrocytes. Chem Pharm Bull (Tokyo) 15:295-302
32. Ziems M, Netzel M, Bitsch I (2000) Biokinetic parameters and metabolism of S-benzoylthiamine-O-monophosphate. Biofactors 11:109-110
33. Emanueli C, Maestri R, Corradi D et al (1999) Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 100:2359-2365
34. Emanueli C, Minasi A, Zacheo A et al (2001) Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103:125-132
35. Condorelli G, Drusco A, Stassi et al (2002) Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A 99:12333-12338
36. Horiuchi S, Araki N, Morino Y (1991) Immunochemical approach to characterize advanced glycation end products of the Maillard reaction: evidence for the presence of a common structure. J Biol Chem 266:7329-7332
37. Kaji Y, Usui T, Oshika T et al (2000) Advanced glycation end products in diabetic corneas. Invest Ophthalmol Vis Sci 41:362-368
38. Chamberlain BR, Buttery JE, Pannall PR (1996) A stable reagent mixture for the whole blood transketolase assay. Ann Clin Biochem 33:352-354
39. Emanueli C, Salis MB, Van Linthout S et al (2004) Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 110:1638-1644
40. Tepper OM, Galiano RD, Capla JM et al (2002) Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106:2781-2786
41. Loomans CJ, de Koning EJ, Staal FJ et al (2004) Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53:195-199
42. Saito N, Kimura M, Kuchiba A, Itokawa Y (1987) Blood thiamine levels in outpatients with diabetes mellitus. J Nutr Sci Vitaminol 33:421-430
43. Havivi E, Bar On H, Reshef A, Raz I (1991) Vitamins and trace metals status in non-insulin dependent diabetes mellitus. Int J Vitam Nutr Res 61:328-333
44. Valerio G, Franzese A, Poggi V, Patrini C, Laforenza U, Tenore A (1999) Lipophilic thiamine treatment in longstanding insulin-dependent diabetes mellitus. Acta Diabetol 36:73-76
45. Ishii H, Jirousek MR, Koya D et al (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:728-731
46. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 88:11555-11558
47. Waltenberger J, Lange J, Kranz A (2000) Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation 102:185-190
48. Lukienko PI, Mel'nichenko NG, Zverninskii IV, Zabrodskaya SV (2000) Antioxidant properties of thiamine. Bull Exp Biol Med 130:874-876
49. Hayashi CM, Nagai R, Miyazaki K et al (2002) Conversion of Amadori products of the Maillard reaction to N-epsilon-(carboxymethyl) lysine by short-term heating: possible detection of artifacts by immunohistochemistry. Lab Invest 82:795-807
50. Brunet A, Bonni A, Zigmond MJ et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868
51. Ohashi H, Takagi H, Oh H et al (2004) Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity. Circ Res 94:785-793
52. Skurk C, Maatz H, Kim HS et al (2004) The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 279:1513-1525